scholarly article | Q13442814 |
P50 | author | Ulka Vaishampayan | Q86981393 |
P2093 | author name string | Harsh Shah | |
P2860 | cites work | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | Q50053735 |
Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes | Q50244769 | ||
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer. | Q52598610 | ||
Apalutamide: First Global Approval. | Q52601554 | ||
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. | Q52660703 | ||
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. | Q52679667 | ||
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. | Q54218117 | ||
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial | Q56804990 | ||
Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer | Q88320357 | ||
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! | Q88758400 | ||
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer | Q89290059 | ||
Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 | ||
Therapy escape mechanisms in the malignant prostate | Q26795611 | ||
Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure | Q26859201 | ||
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 | ||
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 | ||
Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer | Q30278902 | ||
ERG induces taxane resistance in castration-resistant prostate cancer | Q30602046 | ||
ARN-509: a novel antiandrogen for prostate cancer treatment | Q34248790 | ||
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study | Q34415540 | ||
Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer | Q34467551 | ||
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies | Q34483362 | ||
Darolutamide (ODM-201) for the treatment of prostate cancer | Q34556466 | ||
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Q35956276 | ||
Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review | Q35969717 | ||
Androgen deprivation therapy for prostate cancer | Q36193125 | ||
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance | Q36470627 | ||
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial | Q36707077 | ||
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time | Q37227675 | ||
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer | Q38681509 | ||
The evolving role of enzalutamide on the treatment of prostate cancer | Q38720976 | ||
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer | Q38746278 | ||
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer | Q38858948 | ||
Androgen Signaling in Prostate Cancer | Q39227656 | ||
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. | Q40173819 | ||
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial | Q40270987 | ||
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial | Q40950557 | ||
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). | Q43668313 | ||
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer | Q44222779 | ||
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer | Q46463184 | ||
Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease | Q47781853 | ||
P433 | issue | 6 | |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 679-689 | |
P577 | publication date | 2018-12-01 | |
P1433 | published in | Targeted oncology | Q25378200 |
P1476 | title | Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment | |
P478 | volume | 13 |
Q61808652 | Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer | cites work | P2860 |
Search more.